Category: Orbimed News

NEW YORK, May 3, 2023 – OrbiMed is excited to announce the opening of its inaugural London office, located at 22a St. James’s Square. This expansion is a logical culmination of OrbiMed’s many decades of commitment to the European life sciences industry.

“With approximately $1.5 billion currently invested in 50 public or private European companies, OrbiMed is an established leader in the European life sciences industry,” stated Managing Partner Carl Gordon. “We look forward to building on this strong foundation to provide even greater local support for our network of European portfolio companies, entrepreneurs, and limited partners.” Matthew Rizzo, General Partner of OrbiMed said, “As part of this expansion, we will accelerate the availability of credit and financing solutions to support healthcare growth and innovation across Europe.”

OrbiMed’s European business activities include serving as the Portfolio Manager for the Worldwide Healthcare Trust PLC and the Biotech Growth Trust PLC, which currently boast more than $3 billion in combined assets under management.

Dimitrios Weedon, Managing Director, has joined OrbiMed as the initial London-based team member, focusing on structured private credit, growth equity, and royalty monetization opportunities. Further team additions are planned to focus on public and private equity investments. Dimitrios can be reached by email: WeedonD@OrbiMed.com.

About OrbiMed

OrbiMed is a leading healthcare investment firm, with over $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.

Contact
Carter Neild, CFA
Phone: (212) 739.6400
Email: NeildC@OrbiMed.com

NEW YORK, December 7, 2021 – OrbiMed is pleased to announce the promotion of two long-standing team members to General Partner.

Matthew Rizzo and Peter Thompson will join OrbiMed’s six existing General Partners at year-end as management company owners and leaders of the firm. Matthew Rizzo joined OrbiMed in 2010 and leads OrbiMed’s royalty monetization and private credit group. Since that time, OrbiMed has established itself as one of the industry-leading providers of structured royalty/credit healthcare financing solutions, investing nearly $3 billion across 78 royalty and credit investments during the past two decades.

Dr. Peter Thompson joined OrbiMed in 2010, initially as a Venture Partner, and more recently as a Private Equity Partner. Peter has demonstrated organizational and investment leadership, including serving as a Founder or CEO of many OrbiMed portfolio companies. Peter has led numerous transformative investments for the firm, including Synthorx, Principia Biopharma, and VelosBio.

“Peter’s promotion to General Partner is a recognition of his substantial contributions to OrbiMed’s private equity team,” stated Managing Partner Carl Gordon. “We look forward to his growing leadership in the years ahead.”

“We congratulate Matt on his leadership role in OrbiMed’s growth from a niche player to one of the largest providers of private credit and royalty monetization solutions for the life sciences industry,” noted Managing Partner Carter Neild.

“As evidenced by these promotions, OrbiMed is committed to building an institutionalized and enduring organizational structure,” stated Managing Partner Sven Borho. “Our partnership will continue to grow in the years ahead.”

About OrbiMed

OrbiMed is a leading healthcare investment firm, with $18 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.

Contact
Carter Neild, CFA
Phone: (212) 739.6400
Email: NeildC@OrbiMed.com

NEW YORK, November 1, 2021 – OrbiMed is pleased to announce two new team additions who are among the global biotechnology industry’s most talented and capable professionals.

Tal Zaks, M.D., Ph.D., joined OrbiMed as a Venture Partner. Dr. Zaks was recently the Chief Medical Officer at Moderna, where he led the development of the company’s COVID-19 vaccine and other key programs. Previously, Dr. Zaks held senior leadership positions in drug development at major pharmaceutical companies, including Sanofi and GlaxoSmithKline. Dr. Zaks received his M.D. and Ph.D. from Ben-Gurion University and conducted post-doctoral research at the U.S. National Institutes of Health.

Sheila Gujrathi, M.D., joined OrbiMed as a Venture Advisor. Dr. Gujrathi was the Chief Executive Officer and Co-Founder of Gossamer Bio. Prior to Gossamer, Dr. Gujrathi served as the Chief Medical Officer of Receptos, which Celgene acquired. Previously, Dr. Gujrathi held development leadership positions at Bristol-Myers Squibb and Genentech and was a McKinsey consultant. Dr. Gujrathi received
her M.D. and B.S. in biomedical engineering from Northwestern University’s Honors Program in Medical Education and clinically trained at Brigham and Women’s Hospital, UCSF, and Stanford.

OrbiMed ranks among the largest and most prolific life sciences investors in recent decades, backing over 80 start-ups since inception. Over 60 new healthcare therapies have been successfully developed and brought to patients by OrbiMed’s private portfolio companies.

“We are excited to welcome Tal and Sheila to the OrbiMed team,” stated Carl Gordon, a Managing Partner and Head of Private Equity at OrbiMed. “We are confident they will make transformative contributions to the growth and success of OrbiMed’s venture capital investments.”

About OrbiMed
OrbiMed is a leading healthcare investment firm, with $18 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.

Contact
Carter Neild, CFA
Phone: (212) 739.6400
Email: NeildC@OrbiMed.com